Realtime | Geld | Brief | Zeit |
---|---|---|---|
4,560 | 4,660 | 22:52 | |
4,480 | 4,740 | 22:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14:05 | Silence Therapeutics plc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13:36 | Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 157 | Business Wire | Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV
SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025
Silence... ► Artikel lesen | |
13:35 | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings | ||
27.06. | Silence Therapeutics plc - 8-K, Current Report | 4 | SEC Filings | ||
SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
13.06. | H.C. Wainwright reiterates buy rating on Silence Therapeutics stock | 5 | Investing.com | ||
12.06. | Silence Therapeutics plc: Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera | 455 | Business Wire | Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran Company Also Announces SANRECO Phase 2 Study Has Exceeded... ► Artikel lesen | |
08.05. | Silence Therapeutics plc GAAP EPS of -C$0.20 | 4 | Seeking Alpha | ||
08.05. | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
08.05. | Silence Therapeutics plc: Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | 1.098 | Business Wire | Company further extends cash guidance into 2028
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA)... ► Artikel lesen | |
06.05. | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings | ||
06.05. | Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors | 422 | Business Wire | Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors
Silence Therapeutics plc... ► Artikel lesen | |
30.04. | Silence Therapeutics plc - 10-K/A, Annual Report | 2 | SEC Filings | ||
24.04. | Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying | 4 | Insider Monkey | ||
07.03. | H.C. Wainwright maintains $75 target on Silence Therapeutics stock | 3 | Investing.com | ||
05.03. | Silence Therapeutics plc: Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference | 336 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present... ► Artikel lesen | |
05.03. | Morgan Stanley cuts Silence Therapeutics stock target to $45 | 4 | Investing.com | ||
04.03. | Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) | 2 | Benzinga.com | ||
27.02. | Jefferies cuts Silence Therapeutics price target to $30 | 16 | Investing.com | ||
27.02. | Silence Therapeutics plc - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
27.02. | Silence Therapeutics plc - 10-K, Annual Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVO NORDISK | 41,960 | +7,47 % | KI und BioTech - Ein Traumpaar für Rendite! Evotec und Novo Nordisk im Rampenlicht, NetraMark gibt Gas! | Der Biotech-Sektor durchläuft derzeit einen tiefgreifenden Wandel: Big Data und Künstliche Intelligenz revolutionieren die Art und Weise, wie Medikamente erforscht und entwickelt werden. KI-gestützte... ► Artikel lesen | |
GILEAD SCIENCES | 94,55 | -0,08 % | Nervosität steigt, Apple investiert - wer profitiert? - Calling USA | ||
VERTEX PHARMACEUTICALS | 323,00 | -2,49 % | Studie eingestellt: Vertex Pharmaceuticals crasht trotz starker Quartalszahlen! | Die Aktie von Vertex Pharmaceuticals steht am Dienstag vor empfindlichen Verlusten. Starke Quartalszahlen werden von einer eingestellten Studie überschattet. Vertex Pharmaceuticals: Einer der konstantesten... ► Artikel lesen | |
INNOCAN PHARMA | 0,142 | 0,00 % | Innocan Pharma Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
IONIS PHARMACEUTICALS | 35,600 | +1,98 % | Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) | ||
SNDL | 1,468 | +1,52 % | SNDL Inc.: SNDL Announces 2025 Annual and Special Meeting Results | EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ: SNDL) (CSE: SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders... ► Artikel lesen | |
ASSEMBLY BIOSCIENCES | 17,900 | +8,81 % | Assembly Biosciences, Inc.: Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates | - On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates... ► Artikel lesen | |
HAPPY BELLY FOOD GROUP | 0,630 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Rosie's Burgers Announces the Signing of a Franchise Agreement and Secured Location in Abbotsford, British Columbia | Toronto, Ontario--(Newsfile Corp. - August 7, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
ALNYLAM PHARMACEUTICALS | 370,00 | +0,74 % | Alnylam Pharmaceuticals auf Allzeihoch: War's das noch nicht? | Alnylam Pharmaceuticals hat mit den Ergebnissen des zweiten Quartals für eine echte Überraschung gesorgt. Der fulminante Verkaufsstart von Amvuttra hat die Erwartungen weit übertroffen und dem Unternehmen... ► Artikel lesen | |
LIGAND PHARMACEUTICALS | 115,00 | -6,50 % | Ligand Pharmaceuticals: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance | Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million)... ► Artikel lesen | |
MEI PHARMA | 5,100 | +3,24 % | MEI Pharma: Litecoin-Kauf über 100 Millionen Dollar - und jetzt? | MEI Pharma initiiert seine Litecoin-Treasury-Strategie mit einer ersten großen Akquisition der zukunftsträchtigen Kryptowährung. Anleger können langfristig profitieren. 110 Millionen US$ in Litecoin... ► Artikel lesen | |
DARE BIOSCIENCE | 2,010 | -10,67 % | Daré Bioscience, Inc.: Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY Sildenafil Cream | A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of... ► Artikel lesen | |
HYTN INNOVATIONS | 0,090 | 0,00 % | HYTN sichert sich Cannabis-Arzneimittellizenz und erzielt Fortschritte im Zulassungsverfahren für verschreibungspflichtige Arzneimittel für Medikamente auf Cannabinoidbasis | Vancouver, British Columbia - 14. Juli 2025 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein
führendes Unternehmen in der Herstellung... ► Artikel lesen | |
WAVE LIFE SCIENCES | 7,450 | +1,36 % | Wave Life Sciences is a new Buy at Canaccord Genuity on near-term catalysts | ||
AKARI THERAPEUTICS | 0,750 | -4,46 % | Akari Therapeutics Plc: Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers | PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2... ► Artikel lesen |